Next Article in Journal
Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases
Previous Article in Journal
Effect of Essential Oils on Pathogenic Bacteria
Previous Article in Special Issue
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
Pharmaceuticals 2013, 6(12), 1475-1506; doi:10.3390/ph6121475
Review

Glioblastoma Multiforme Therapy and Mechanisms of Resistance

1,†
, 1,†
, 2
 and 1,*
1 Department of Biochemistry and Molecular Pharmacology and Department of Cancer Biology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA 2 School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK These authors contributed equally to works.
* Author to whom correspondence should be addressed.
Received: 11 September 2013 / Revised: 4 November 2013 / Accepted: 12 November 2013 / Published: 25 November 2013
(This article belongs to the Special Issue Chemotherapeutic Agents)
View Full-Text   |   Download PDF [315 KB, 26 November 2013; original version 25 November 2013]   |   Browse Figures

Abstract

Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.
Keywords: angiogenesis; autophagy; imidazotetrazine; MGMT; DNA repair; temozolomide; cancer stem cells angiogenesis; autophagy; imidazotetrazine; MGMT; DNA repair; temozolomide; cancer stem cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Ramirez, Y.P.; Weatherbee, J.L.; Wheelhouse, R.T.; Ross, A.H. Glioblastoma Multiforme Therapy and Mechanisms of Resistance. Pharmaceuticals 2013, 6, 1475-1506.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert